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Objectives. To compare the analgesic efficacy of intrathecal clonidine and fentanyl added to bupivacaine after cesarean section.
Methods. Ninety patients scheduled for cesarean section under spinal anesthesia were randomly allocated to one of the three
following groups to receive bupivacaine 10mg combined with 75 𝜇g clonidine (group C), bupivacaine 10mg combined with 0.5mL
fentanyl (group F), and bupivacaine 10mg combined with 0.5mL distilled water (group P), intrathecally. The time to first analgesic
request, analgesic requirement in the first 24 hours after surgery, sensory and motor blockade onset time, duration of sensory
and motor blockade, the incidence of hypotension, ephedrine requirements, bradycardia, and hypoxemia were recorded. Results.
The duration of anesthesia in clonidine group (275.10 ± 96.09) was longer compared to the placebo (211.73 ± 74.80) and fentanyl
(192.33 ± 30.36) groups. This difference between group C versus F (𝑃 = 0.006) and P groups (𝑃 < 0.001) was significant. Similarly,
the mean time to first analgesic request was also longer in group C (519.44 ± 86.25) than in groups F (277.88 ± 94.25) and P
(235.43 ± 22.35min). This difference between group C versus F (𝑃 < 0.001) and P groups (𝑃 < 0.001) was significant. Conclusion.
Intrathecal clonidine 75 𝜇g with bupivacaine prolonged the time to first analgesic request compared to fentanyl; however, the total
analgesic consumption within the first 24 h postoperative was similar in fentanyl and clonidine groups following cesarean section.
This trial is registered with ACTRN12611000909921 and ClinicalTrials.gov NCT01425658.
1. Introduction
Pain control after cesarean improves breastfeeding and sat-
isfaction of mother. In addition, inadequate analgesia leads
to elevated plasma catecholamine concentrations, resulting
in adverse effect on all organ systems [1]. Neuraxial analgesia
using only local anesthetic often provides suboptimal analge-
sia with higher side effects. Many drugs have been adjusted to
local anesthetics to provide optimal analgesia with lower side
effects such as opioids, epinephrine, ketamine, midazolam,
clonidine, andmagnesium [2, 3]. Opioids are usually used for
providing better analgesia and reducing the side effects. Fen-
tanyl exhibits close structural similarities to local anesthetics
and has demonstrable local anesthetic effect on sensory C
primary afferent nerve fibers, which may facilitate analgesic
effects [4, 5]. Furthermore, fentanyl is the most frequently
intrathecal lipophilic opioid used as analgesic agentwithmin-
imal cephalad spread making it the least likely of all the
intrathecal opioids to cause delayed respiratory depression
[5]. However, in parturients, the advantageous analgesia has
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Figure 1: Consort flow of diagram.
to be balanced against maternal and fetal side effects such
as bradycardia, respiratory depression, arterial hypotension,
nausea, vomiting, and pruritus. Furthermore, it is reported
that a single administration of an opioid may also induce a
long lasting increase of threshold pain sensitivity, leading to
delayed hyperalgesia [6]. On the contrary, it is reported that
clonidine by stimulation of 𝛼
2
adrenoreceptors beyond the
analgesic effects possesses antihyperalgesic properties [7–9].
Clonidine mimics the effects of norepinephrine and it anti-
hyperalgesic mechanisms that partly depend on fortification
of noradrenergic inhibitory controls in the dorsal horn of the
spinal cord [10]. The safety of intrathecal clonidine has been
extensively evaluated in animals, humans, and obstetrical
anesthesia [6, 11–16]. Also it is reported that clonidine admin-
istrated via intrathecal route was undetectable in the fetal
circulation with no obvious effect on the neonatal Apgar
scores [12, 16].
We hypothesized that clonidinemay provide a better pain
relief after cesarean section compared to fentanyl. In addition,
unlike spinal opioids, clonidine does not produce pruritus,
hyperalgesia, or respiratory depression. To test our hypoth-
esis, we designed this randomized-double-blind, placebo-
controlled study to compare the postoperative analgesic effect
of intrathecal clonidine and fentanyl added to bupivacaine in
patients undergoing cesarean section.
2. Methods
After approval of the Institutional Ethical Committee and
written informed consent, Ninety-six patients 18–45 years old
ASA physical status I or II, scheduled for cesarean section
under spinal anesthesia, were enrolled in a prospective,
double-blind, randomized parallel study. The recommen-
dations by the Consolidated Standards of Reporting Trials
(CONSORT) for reporting a randomized, controlled clinical
trial [17] were followed (Figure 1). Exclusion criteria included
significant coexistence of conditions such as hepatorenal and
cardiovascular diseases, any contraindication to regional
anesthesia such as local infection or bleeding disorders,
allergy to bupivacaine or clonidine, long-term opioid use,
or a history of chronic pain. The patients were randomly
allocated to one of three groups of 30 members each by using
the computer-generated randomization list. Blinding was
achieved through the use of equal amounts of drugs (2.5mL),
while each syringe was labeled as A, B, and C according to its
contents. Identical coded syringes prepared by the personnel
not involved in the study were randomly handed to the
anesthetists, who were unaware of the identity of the drugs.
The clonidine group received bupivacaine 10mg combined
with 75 𝜇g of preservative free clonidine; the fentanyl group
received bupivacaine 10mg combined with 25 𝜇g fentanyl;
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and the placebo group received bupivacaine 10mg combined
with 0.5mL distilled water, intrathecally. All patients received
an intravenous preload of 5–7mL/kg lactated Ringer’s solu-
tion before a subarachnoid block. Later, using an aseptic
technique, a 25-gauge Quincke needle was inserted intrathe-
cally via a midline approach into the L4-5 interspaces by the
anesthetist who was unaware of patient assignment while
the patient was in sitting position. After a successful dural
puncture, the anesthetic solution was injected. The primary
outcomes of this randomized, double-blind and placebo-
controlled clinical trial are to evaluate the time to first
requirement of analgesic supplement and total analgesic con-
sumption in the first 24 h postoperative. The secondary out-
comes included the assessment of sensory block onset time,
onset of motor block, duration of blockade, hemodynamic
variables, the incidence of hypotension, ephedrine require-
ments, bradycardia, hypoxemia (saturation of peripheral
oxygen (SpO
2
) < 90), and adverse events such as sedation,
dizziness, pruritus, and postoperative nausea and vomiting.
In this study, the postoperative analgesia was defined as
the time to first requirement of analgesic supplement from the
time of injection. No additional analgesic was administered
unless requested by the patient. Sensory block was assessed
by a pinprick test. The onset of sensory block was defined
as the time between the end of injection of the intrathecal
anesthetic and the absence of pain at the T10 dermatome;
the duration of sensory block was defined as the time for
regression of the sensory from the maximum block height to
the T10 dermatome as evaluated by pinprick. The maximum
level of sensory block was evaluated by pinprick after 20min
following completion of injection. Motor block was assessed
by the modified Bromage score (0: no motor loss; 1: inability
to flex the hip; 2: inability to flex the knee; and 3: inability
to flex the ankle); the onset of motor block was defined
as the time from intrathecal injection to Bromage block 1,
whereas the duration of motor block was assumed when the
modified Bromage score was zero. The duration of spinal
anesthesia was defined as the period from spinal injection to
the first occasion when the patient complained of pain in the
postoperative period. Patients were preoperatively instructed
to use the verbal rating scale (VRS) from 0 to 10 (0: no pain,
and 10:maximum imaginable pain) for pain assessment. If the
VRS exceeded four and the patient requested a supplement
analgesic, diclofenac Na sup. 100mg every 8 hours was given
to relieve the postoperative pain as needed (q 8 h PRN). If
the time course following the administration of diclofenac
Na decreased to less than 8 h and the patient made another
request for supplement analgesic, pethidine 25mg IV was
given.
The mean arterial pressure (MAP), heart rate (HR), and
peripheral oxygen saturation (SpO
2
) were recorded by an
anesthetist blinded to the patient group 5min before the
intrathecal injection and also 2, 4, 6, 8, 10, 15, and 20min after
injection. If systolic blood pressure (SBP) was 20% below the
baseline (5min before the intrathecal injection) or less than
90mmHg, ephedrine 5mg was administered intravenously.
Also, if HRwas less than 50 beats/min, 0.5mg of atropine sul-
fate was administered intravenously. A follow-up telephone
call was made 24 h after surgery and again 1 and 6 months
later, during which the patients were asked about the side
effects and dysesthesia of the lower limbs or buttocks. To
calculate the sample size, data from previous similar studies
were taken into consideration [2, 3, 12, 14]. A sample size
of 25 patients per group was required to detect a 20min
difference in the median duration of analgesia between the
groups using the Mann-Whitney 𝑈 test, with a power of 0.9
and an 𝛼 equal to 0.05. We included 30 patients in each
group to allow for dropouts and protocol violations. Data
were analyzed using SPSS (SPSS 15.0, SPSS Inc, Chicago,
IL, USA). Continuous variables were tested for normal
distribution by the Kolmogorov-Smirnov test. Parametric
data were expressed as mean and standard deviation (SD)
and analyzed by independent 𝑡-test. Nonparametric data
were expressed as median and interquartile range (IQR) and
analyzed using the Mann-Whitney 𝑈 test. The effect of time
on hemodynamic parameters was analyzed using repeated
measurement analysis of variance. The 𝜒2 test was used to
analyze the incidence of side effects. Pain scores, motor
scores, and sensory level were evaluated within the groups
using the Wilcoxon’s signed rank test. A 𝑃 value <0.05 was
considered as significant, statistically.
3. Results
A total of 96 patients initially enrolled in this study, 6
patients had to be excluded because of logistical reasons or
other violations of the study protocol. Ninety patients were
included and randomly assigned to their treatment groups
(Figure 1).
There were no significant differences in age, height, and
weight among the three groups. The duration of surgery was
also similar (Table 1).
Themean onset of sensory block was 90±23 sec in group
C 95.33±39.17 sec in group F and 78.5±26.00 sec in group P.
The difference between group C versus group F (𝑃 = 0.523)
and P (0.075) was insignificant. Similarly, this difference in
groups F and P was also insignificant (𝑃 = 0.055). The mean
duration of sensory block in group C (169.66 ± 25.69min)
was longer than group F (122.23 ± 32.78min) and group
P (133.53 ± 32.68min). The difference between group C
versus group F (𝑃 < 0.001) and P (𝑃 < 0.001) was
significant, but the difference between groups F and P (𝑃 =
0.186) was found to be insignificant.Themean onset ofmotor
block was 81.33 ± 26.71 in group C, 80.00 ± 30.62 in group
F, and 81.83 ± 27.21 sec in group P. The difference between
group C versus group F (𝑃 = 0.858) and P (𝑃 = 0.943)
was insignificant. Similarly, the difference in groups F and P
was insignificant (𝑃 = 0.807). The median value found for
the maximum height of block was T6 for all three groups.
The mean duration of motor blockade time was significantly
longer in group C (182.66 ± 33.12min) than F (136.76 ±
28.85min) and P groups (143.16 ± 33.94). The difference
in mean duration of motor blockade time between group C
versus F (𝑃 < 0.001) and P groups (𝑃 < 0.001) was significant
whereas no significant difference in duration of motor block
between F and P groups was found (𝑃 = 0.435). The
duration of anesthesia in clonidine group (275.10±96.09) was
longer compared to the placebo (211.73±74.80) and fentanyl
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Table 1: Demographic data for three study groups.
Groups Group C (𝑛 = 30) Group F (𝑛 = 30) Group P (𝑛 = 30)
Age (years) 30.43 ± 3.70 30.20 ± 5.41 29.16 ± 5.11
Weight (kg) 88.5 ± 15.4 88.5 ± 13.6 89.7 ± 11.9
Height (cm) 166 ± 4.6 160 ± 8.4 162 ± 6.1
Duration of surgery (min) 85.63 ± 15.70 79.16 ± 20.11 81.70 ± 18.76
Values are presented as mean ± SD. C: clonidine, F: fentanyl, and P: placebo. There are no significant differences among the three groups.
Table 2: Characteristics of spinal anesthesia.
Groups Group C (𝑛 = 30) Group F (𝑛 = 30) Group P (𝑛 = 30) 𝑃
Onset time of sensory block (second) 90 ± 23 95.33 ± 39.17 78.5 ± 26.00 NS
Duration of sensory block (min) 169.66 ± 25.69 122.23 ± 32.78 133.53 ± 32.68 <0.001
Onset time of motor block (second) 81.33 ± 26.71 80.00 ± 30.62 81.83 ± 27.21 NS
Duration of motor block (min) 182.66 ± 33.12 136.76 ± 28.85 143.16 ± 33.94 <0.001
Time to first request of analgesic (min) 519.44 ± 86.25 277.88 ± 94.25 235.43 ± 22.35 <0.001
Duration of spinal anesthesia 275.10 ± 96.09 211.73 ± 74.80 192.33 ± 30.36 <0.001
Total ephedrine requirement 10.83 ± 5.26 4.16 ± 5.84 2.16 ± 5.52 <0.001
Total analgesic consumption in 24 h (number of analgesic request) 2 (2-2) 2 (1–3) 3 (2-3) 0.011
Values are presented as mean ± SD or median IQR C: clonidine, F: fentanyl, and NS: nonsignificant (𝑃 > 0.05).
(192.33±30.36) groups. As shown in Table 2, the patients who
were given clonidine had a significantly prolonged duration
of anesthesia compared with control (𝑃 < 0.001) and F
groups (𝑃 = 0.006). As to the duration of anesthesia, the
mean time to first analgesic request was also significantly
longer in group C (519.44±86.25) than in groups F (277.88±
94.25) and P (235.43 ± 22.35min). This difference between
group C versus F (𝑃 < 0.001) and P groups (𝑃 < 0.001)
was significant. Likewise, the difference between groups F
and P was also significant (𝑃 = 0.022). The total number
of analgesic request by patients during 24 hours after surgery
in clonidine group was significantly smaller than in control
group (𝑃 = 0.002). Total analgesic consumption during
24 hours after surgery failed to demonstrate a significant
difference between F and C groups (𝑃 = 0.318).
As shown in Table 3, the mean variation of mean arterial
pressure and heart rate was defined as the difference between
the highest and the lowest mean arterial pressure and heart
rate in each patient. The mean variation of MAP was 50.70 ±
21.65 in group C, 33.73 ± 10.73 in group P, and 50.00 ±
76.14 in group F. This difference between group C versus P
(𝑃 < 0.001) was significant whereas no significant difference
between F versus C (𝑃 = 0.962) and P (𝑃 = 0.251) groups
was found. The overall difference in ephedrine requirement
between the three groups was significant, statistically (𝑃 <
0.001). The mean variation of HR was 34.33 ± 9.7 in group
C, 33.43 ± 10.73 in group P, and 32.86 ± 10.17 in group F.
The difference between group C versus P (𝑃 = 0.761) and
F (𝑃 = 0.571) groups was also insignificant as it was for the
difference between groups F and P (𝑃 = 0.851). As shown in
Figure 2, the three groups were found to have no significant
difference in terms of other intraoperative and postoperative
side effects including pruritus, nausea, vomiting, headache,
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Figure 2: Side effects observed in three study groups. C: clonidine,
F: fentanyl, and P: placebo. ∗Significant difference between the three
groups.
shivering, and respiratory depression. No patient in either
group showed any sensory ormotor complications within the
next six months followup after surgery. All newborns in our
study were free of any adverse effect.
4. Discussion
Based on the data found in our study, it was concluded that
administration of intrathecal clonidine 75𝜇g with bupiva-
caine prolonged intraoperative anesthesia and the time to
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Table 3: Hemodynamic variables in the three groups.
Groups Group C (𝑛 = 30) Group P (𝑛 = 30) Group F (𝑛 = 30) 𝑃
MAP 5min before SA 97.23 ± 7.62 94.76 ± 8.82 95.05 ± 5.36 NS
MAP 2min after SA 73.25 ± 17.46 85.78 ± 11.13 74.76 ± 15.95 0.003
MAP 4min after SA 69.54 ± 15.39 79.57 ± 11.69 74.93 ± 13.71 0.021
MAP 6min after SA 89.84 ± 34.82 73.98 ± 13.39 82.12 ± 12.61 0.030
MAP 8min after SA 91.72 ± 20.19 79.08 ± 13.00 87.54 ± 10.57 0.006
MAP 10min after SA 92.96 ± 16.70 75.63 ± 12.55 89.11 ± 7.93 <0.001
MAP 15min after SA 92.52 ± 17.22 78.92 ± 11.95 92.66 ± 9.09 0.001
MAP 20min after SA 87.20 ± 15.81 78.14 ± 8.94 107.70 ± 76.69 0.041
MAP 25min after SA 83.64 ± 17.55 75.21 ± 9.31 86.38 ± 4.66 0.001
MAP 30min after SA 78.43 ± 13.34 66.58 ± 8.87 89.73 ± 5.56 <0.001
HR 5min before SA 99.40 ± 11.88 97.90 ± 15.40 98.73 ± 13.61 NS
HR 2min after SA 96.46 ± 16.05 101.20 ± 19.13 101.73 ± 16.15 NS
HR 4min after SA 89.13 ± 13.62 96.46 ± 17.38 97.26 ± 15.03 NS
HR 6min after SA 87.50 ± 13.43 97.16 ± 19.61 98.90 ± 17.58 0.024
HR 8min after SA 84.40 ± 10.87 95.06 ± 20.14 92.73 ± 17.36 0.037
HR 10min after SA 87.36 ± 13.29 96.23 ± 22.76 91.70 ± 13.68 NS
HR 15min after SA 83.46 ± 10.48 101.76 ± 17.82 89.13 ± 14.32 <0.001
HR 20min after SA 85.56 ± 12.38 102.26 ± 20.37 88.26 ± 14.49 <0.001
HR 25min after SA 88.73 ± 11.46 99.50 ± 18.04 90.86 ± 12.33 0.011
HR 30min after SA 86.76 ± 9.20 97.83 ± 17.07 89.50 ± 11.36 0.004
Data are presented asmean± SD. C: clonidine, F: fentanyl, P: placebo,MAP:mean arterial blood pressure (mmHg), HR: heart rate (bpm), SA: spinal anesthesia,
and NS: nonsignificant.
first analgesic request after cesarean delivery compared to
fentanyl and control groups. These findings are consistent
with previous studies [18, 19]. Analgesic properties of cloni-
dine have been shown to depend on the activation of 𝛼
2
receptors located in the dorsal horn. Presynaptic stimulation
of 𝛼
2
receptors inhibits neurotransmitter release and postsy-
naptic stimulation prevents neuronal transmission through
hyperpolarisation [10].
The second observation which should be emphasized is
that although intrathecal clonidine 75𝜇g with bupivacaine
prolonged intraoperative anesthesia and the time to first
analgesic request compared to fentanyl yet the total analgesic
consumption in the first 24 h postoperative was similar in
fentanyl and clonidine groups after elective cesarean delivery.
The possible explanation for this finding is that the analgesic
effect of clonidine follows a dose-dependent manner. Eise-
nach et al. reported that a dose of 150 𝜇g clonidine is required
to observe antihyperalgesic effect, while a lower dose (50𝜇g)
is ineffective [8, 18, 20]. The selected dose of intrathecal
clonidine in current study was based on several reasons.
Firstly, intrathecal clonidine displays the risk of adverse
intraoperative hemodynamic effects. Rochette et al. showed
that clonidine at a dose of 1 𝜇g/kg was not associated with
hemodynamic disturbance [21]. Also, Bajwa et al. [22] found
that the optimal dose for clonidine to produce effective anal-
gesia without inducing hypotension in emergency cesarean
section is 37.5 𝜇g. However, most studies have reported that
although clonidine at a lower intrathecal dose less than
0.5 𝜇g/kg body weight was devoid of its diverse side effects, at
the same time the antinociceptive effect of this drug was also
reduced significantly [7, 12–14, 16]. Secondly, it is reported
that intrathecal clonidine possesses an analgesic plateau effect
at 75 𝜇g and higher doses could only increase the duration but
not the intensity of analgesia [8].
The third finding which should be considered is that
intrathecal clonidine clearly increases the duration of both
sensory block and motor block as well as postoperative
pain relief. This finding is also consistent with the previous
studies [18, 23, 24]. The mechanism of clonidine-induced
potentiation of sensory block in spinal anesthesia is reported
to be dependent on presynaptic (decrease in transmitter
release) and postsynaptic (increase in hyperpolarization)
action [25, 26].
The fourth finding which should be taken into account is
that transient hypotension episodes and vasopressor require-
ment in clonidine group were significantly greater than F
and P groups, a finding in agreement with previous studies
[27, 28]. Except for sympatholytic action of clonidine and
profound analgesia which also reduces sympathetic activity,
no other clear explanation is available. In contrast, some
studies have reported that clonidine at doses between 37.5 and
150 𝜇g failed to cause a significant decrease in blood pressure
when added to a high dose of bupivacaine (18mg) [13, 29].
However, these apparently controversial findings may be due
to either the difference in bupivacaine and clonidine doses
or dissimilarity in population and the type of surgeries. The
fifthobservationwhich should be noted is that clonidine lacks
the ability to prevent postspinal shivering; by contrast, it is
confirmed that clonidine, when administered intravenously,
is an effective drug to prevent shivering in patients undergo-
ing spinal anesthesia [30, 31], a finding compatible with that
found in a study by Jeon et al. [32]. The possible reason for
this finding could be attributed to the inability of clonidine to
inhibit afferent thermal conduction at the level of spinal cord.
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All newborns in our study were free of any adverse effect. We
concluded that intrathecal clonidine 75 𝜇g with bupivacaine
prolonged intraoperative anesthesia and the time to first
analgesic request compared to fentanyl, however, the total
analgesic consumption in the first 24 h postoperative was
similar in fentanyl and clonidine groups following elective
cesarean delivery. Further studies are needed to evaluate the
analgesic efficacy of clonidinewith other neuraxial drug com-
binations such as epinephrine, ketamine, and magnesium
to provide better analgesia and reduce the incidence and
severity of side effects.
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